Kestra Advisory Services’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Kestra Advisory Services’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-4,101	Closed	-$343K	–	2924
2024 Q4	$343K	Buy	4,101 +535	+15%	+$44K	﹤0.01%	2137
2024 Q3	$261K	Sell	3,566 -30	-0.8%	-$2.25K	﹤0.01%	2188
2024 Q2	$246K	Sell	3,596 -494	-12%	-$34.3K	﹤0.01%	2261
2024 Q1	$283K	Sell	4,090 -1,987	-33%	-$137K	﹤0.01%	2037
2023 Q4	$435K	Sell	6,077 -533	-8%	-$30.7K	﹤0.01%	1607
2023 Q3	$344K	Buy	+6,610	New	+$385K	﹤0.01%	1579
2022 Q1	–	Sell	-6,045	Closed	-$316K	–	2142
2021 Q4	$316K	Buy	+6,045	New	+$254K	﹤0.01%	1578
2021 Q3	–	Sell	-5,000	Closed	-$204K	–	2190
2021 Q2	$204K	Buy	+5,000	New	+$185K	﹤0.01%	1859

Other funds holding ITCI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Kestra Advisory Services's ITCI Position: Q1 2025 in Review

Kestra Advisory Services sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 4,101 shares — an estimated $343K sold.

Kestra Advisory Services first reported a position in ITCI in Q2 2021 and held it in 8 quarters. The position peaked at $435K in Q4 2023. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

Kestra Advisory Services reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
Kestra Advisory Services sold 4,101 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $343K.
Kestra Advisory Services first reported a position in Intra-Cellular Therapies Inc. in Q2 2021 and held it in 8 quarters.
Kestra Advisory Services's Intra-Cellular Therapies Inc. position peaked at $435K in Q4 2023.
395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Kestra Advisory Services's 13F filing for Q1 2025, filed 14 May 2025.